Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...

Across the recent three months, 5 analysts have shared their insights on Dianthus Therapeutics DNTH, expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...

Dianthus Therapeutics (NASDAQ:DNTH) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of ...

It’s not surprising that the most important drug candidates and targets are super challenging when it comes to affinity screening. Immobilization-dependent techniques like SPR, and sample-consuming ...

Visit a quote page and your recently viewed tickers will be displayed here.

Shares of Dianthus TherapeuticsDNTH surged to an 18-month high Monday after the company's autoimmune disease treatment succeeded in a midstage study. Now, Dianthus is planning to send its drug, ...